Apo-amitriptyline 10mg: Ndma Impurity

APO-AMITRIPTYLINE 10mg Recall Summary APO-AMITRIPTYLINE 10mg tablets are being recalled across Canada because they contain NDMA, an impurity that can pose a health risk. This is a Class I recall, meaning there is a serious potential health hazard. The recall affects all doses of this medication that were distributed in Canada.

Product

APO-AMITRIPTYLINE 10mg

Reason

Contamination - Product safety

Classification

Class I

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2023-02-07

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/25fe885c-c0cd-4e26-8eb4-e9f63f25922a